If Z160 doesn't pan out, ZLCS is in trouble. If you buy this company, you are "betting" Z is going to be a success. Early on, it looks good but there is a long way to go. Like pattonjim suggests, this is a lone, I mean long term hold that requires quite a bit of patience.
With this type of stock ,earnings are inconsequential. No one is in this thing for normal organic growth. If so they are fools. I mean look at their metrics... 5x Price to sales; 3X price to book; astronomically negative operating margins and return on assets; miniscule royalties from Exalgo etc. People are investing in this as if it were a start up company and because of the potential ZLCS has in its pipeline. I would like to emphasize the term 'potential'. The first impotant leg is the PII data. PI following positive preclinical is a given. The rubber starts to hit the road in the PII data; though the lions share of drugs fail at PIII. Z944, the T-type calcium channel blocker for acute and inflammatory pain is not a well proven mechanism. Much of Z-944 is predicated upon supposition so I have less faith in Z-944 than in Z-160. This stock is a risk and there is no way around that. However to get back to your original question, the earnings report is really meaningless for ZLCS and I do not expect much of a move either way.
Zing: What are you referring to when you say when you say "its not a well proven mechanism" ??? Heck no its not a well proven mechanism. That's why they have a first in class situation. If you have a sane response lets get into a debate otherwise pack the tent and head to another board with our garbage.
Jim Lone and calm and not listen to this type of trash